Page 32 - Service Testing News Today

By Chris Wack BioCardia shares were down 46% at $1.06, a new 52-week low, after the company said it is pausing its ongoing Phase 3 pivotal CardiAMP Cell...

By Denny Jacob Gilead Sciences has discontinued its Phase 3 study of magrolimab in higher-risk myelodysplastic syndromes. The biopharmaceutical company said...

By Chris Wack Nanobiotix shares were up 9% at $7.73 after the company said the first patient has been injected in a Phase 1/2 study evaluating NBTXR3...

By Colin Kellaher Vir Biotechnology on Thursday said a Phase 2 study of its VIR-2482 candidate for the prevention of symptomatic influenza A illness missed...

By Colin Kellaher Vir Biotechnology shares slid more than 40% and hit a new multi-year low Thursday after the immunology company reported the failure of a...

This report gives an insight into the global Automotive Quality Service market and predicts the future growth prospects and the trends that may exhibit in...

By Colin Kellaher Shares of Acumen Pharmaceuticals jumped nearly 40% in premarket trading Monday after the clinical-stage biopharmaceutical company reported...

By Chris Wack Arrowhead Pharmaceuticals said Monday that it has filed an application in New Zealand to initiate a Phase 1/2 clinical trial of ARO-DUX4, its...

By Adriano Marchese ProMIS Neurosciences shares more than doubled Monday morning after the company said it presented additional positive preclinical data...

A Phase 3 trial shows that Eli Lilly's investigational Alzheimer’s treatment donanemab significantly slowed cognitive and functional decline in people in the...